|S-1/AJan 26, 4:06 PM ET

Invea Therapeutics, Inc S-1/A

S-1/A · Invea Therapeutics, Inc · Filed Jan 26, 2024

Documents

28 files
  • S-1
  • EX-23.1
  • GRAPHIC
    lg_inveatherapeutics-4c.jpg

    GRAPHIC

  • GRAPHIC
    fc_pipelinee-4c.jpg

    GRAPHIC

  • GRAPHIC
    tbl_majortheraoeutic-4c.jpg

    GRAPHIC

  • GRAPHIC
    fc_fig01invea-4c.jpg

    GRAPHIC

  • GRAPHIC
    fc_imidsubmet-4c.jpg

    GRAPHIC

  • GRAPHIC
    fc_fig03dysreg-4c.jpg

    GRAPHIC

  • GRAPHIC
    fc_fig04cellbio-4c.jpg

    GRAPHIC

  • GRAPHIC
    fc_fig05inflama-4c.jpg

    GRAPHIC

  • GRAPHIC
    fc_fig06mediator-4c.jpg

    GRAPHIC

  • GRAPHIC
    tb_adseverity-4c.jpg

    GRAPHIC

  • GRAPHIC
    tb_placebo-4c.jpg

    GRAPHIC

  • GRAPHIC
    lc_fig08primary-bw.jpg

    GRAPHIC

  • GRAPHIC
    lc_fig09igascor01-bw.jpg

    GRAPHIC

  • GRAPHIC
    lc_fig09igascor02-bw.jpg

    GRAPHIC

  • GRAPHIC
    tb_enzyme-4c.jpg

    GRAPHIC

  • GRAPHIC
    tb_report-4c.jpg

    GRAPHIC

  • GRAPHIC
    lc_fig12plasma-bw.jpg

    GRAPHIC

  • GRAPHIC
    tb_system-4c.jpg

    GRAPHIC

  • GRAPHIC
    lc_fig14inva8001-bw.jpg

    GRAPHIC

  • GRAPHIC
    tb_system01-4c.jpg

    GRAPHIC

  • GRAPHIC
    tb_assesment-4c.jpg

    GRAPHIC

  • GRAPHIC
    tb_system02-4c.jpg

    GRAPHIC

  • GRAPHIC
    ph_intactskin-4c.jpg

    GRAPHIC

  • GRAPHIC
    tb_mean-bw.jpg

    GRAPHIC

  • GRAPHIC
    fc_lpsatpmousemodel-4c.jpg

    GRAPHIC

  • GRAPHIC
    bc_plasma-4c.jpg

    GRAPHIC